Outcome Analysis of Severe Hyperbilirubinemia in Neonates Undergoing Exchange Transfusion

Abstract

Objective Severe neonatal hyperbilirubinemia can cause neurological disability or mortality if not effectively managed. Exchange transfusion (ET) is an efficient treatment to prevent bilirubin neurotoxicity. The purpose of this study was to evaluate outcomes in severe neonatal hyperbilirubinemia with ET and to identify the potential risk factors for poor outcomes.

Methods Newborns of ≥28 weeks of gestational age with severe hyperbilirubinemia who underwent ET from January 2015 to August 2019 were included. Demographic data were recorded and analyzed according to follow-up outcomes at 12 months of corrected age. Poor outcomes were defined as death due to bilirubin encephalopathy or survival with at least one of the following complications: cerebral palsy, psychomotor retardation (psychomotor developmental index < 70), mental retardation (mental developmental index < 70), or hearing impairment.

Results A total of 524 infants were eligible for recruitment to the study, and 62 infants were lost to follow-up. The outcome data from 462 infants were used for grouping analysis, of which 398 cases (86.1%) had normal outcomes and 64 cases (13.9%) suffered poor outcomes. Bivariate logistic regression analysis showed that peak total serum bilirubin (TSB) (odds ratio [OR] = 1.011, 95% confidence interval [CI] = 1.008–1.015, p = 0.000) and sepsis (OR = 4.352, 95% CI = 2.013–9.409, p < 0.001) were associated with poor outcomes of hyperbilirubinemia. Receiver operator characteristic curve analysis showed that peak TSB ≥452.9 µmol/L could predict poor outcomes of severe hyperbilirubinemia.

Conclusion Peak TSB and sepsis were associated with poor outcomes in infants with severe hyperbilirubinemia, and peak TSB ≥452.9 µmol/L could predict poor outcomes.

Keywords

acute bilirubin encephalopathy - hyperbilirubinemia - exchange transfusion - cerebral palsy - neurodevelopmental outcomes

• References

• 1 Bhutani VK, Stark AR, Lazzeroni LC. et al; Initial Clinical Testing Evaluation and Risk Assessment for Universal Screening for Hyperbilirubinemia Study Group. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. J Pediatr 2013; 162 (03) 477-482.e1
• 2 Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage–mechanisms and management approaches. N Engl J Med 2013; 369 (21) 2021-2030
• 3 Lai K, Song XL, Shi HS. et al. Bilirubin enhances the activity of ASIC channels to exacerbate neurotoxicity in neonatal hyperbilirubinemia in mice. Sci Transl Med 2020; 12 (530) eaax1337
• 4 Gamaleldin R, Iskander I, Seoud I. et al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics 2011; 128 (04) e925-e931
• 5 Olusanya BO, Osibanjo FB, Slusher TM. Risk factors for severe neonatal hyperbilirubinemia in low and middle-income countries: a systematic review and meta-analysis. PLoS One 2015; 10 (02) e0117229
• 6 Wu YW, Kuzniewicz MW, Wickremasinghe AC. et al. Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study. JAMA Pediatr 2015; 169 (03) 239-246
• 7 Yu C, Li H, Zhang Q, He H, Chen X, Hua Z. Report about term infants with severe hyperbilirubinemia undergoing exchange transfusion in Southwestern China during an 11-year period, from 2001 to 2011. PLoS One 2017; 12 (06) e0179550
• 8 Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992 to 2004). J Perinatol 2009; 29 (Suppl. 01) S25-S45
• 9 Yuan X, Song J, Gao L. et al. Early amplitude-integrated electroencephalography predicts long-term outcomes in term and near-term newborns with severe hyperbilirubinemia. Pediatr Neurol 2019; 98: 68-73
• 10 Oh W, Tyson JE, Fanaroff AA. et al; National Institute of Child Health and Human Development Neonatal Research Network. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics 2003; 112 (04) 773-779
• 11 Kang W, Yuan X, Zhang Y. et al. Early prediction of adverse outcomes in infants with acute bilirubin encephalopathy. Ann Clin Transl Neurol 2020; 7 (07) 1141-1147
• 12 Dani C, Becciani S, Pratesi S. Changes in total serum bilirubin during phototherapy in late preterm and term infants with non-haemolytic hyperbilirubinemia. Early Hum Dev 2019; 131: 41-44
• 13 Can E, Verim A, Başer E, İnan N. Auditory neuropathy in late preterm infants treated with phototherapy for hyperbilirubinemia. Int J Audiol 2015; 54 (02) 89-95
• 14 Okwundu CI, Okoromah CA, Shah PS. Cochrane review: prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Evid Based Child Health 2013; 8 (01) 204-249
• 15 Chen HN, Lee ML, Tsao LY. Exchange transfusion using peripheral vessels is safe and effective in newborn infants. Pediatrics 2008; 122 (04) e905-e910
• 16 Wolf MF, Childers J, Gray KD. et al. Exchange transfusion safety and outcomes in neonatal hyperbilirubinemia. J Perinatol 2020; 40 (10) 1506-1512
• 17 Amin SB, Wang H, Laroia N, Orlando M. Unbound bilirubin and auditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice. J Pediatr 2016; 173: 84-89
• 18 Maisels MJ, Baltz RD, Bhutani VK. et al; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114 (01) 297-316
• 19 Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol 2012; 32 (09) 660-664
• 20 Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet 2017; 390 (10104): 1770-1780
• 21 Christensen RD, Yaish HM. Hemolytic disorders causing severe neonatal hyperbilirubinemia. Clin Perinatol 2015; 42 (03) 515-527
• 22 Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr 2002; 140 (04) 396-403
• 23 Morioka I, Nakamura H, Koda T. et al. Serum unbound bilirubin as a predictor for clinical kernicterus in extremely low birth weight infants at a late age in the neonatal intensive care unit. Brain Dev 2015; 37 (08) 753-757
• 24 Bhutani VK, Wong RJ, Stevenson DK. Hyperbilirubinemia in preterm neonates. Clin Perinatol 2016; 43 (02) 215-232
• 25 Hakan N, Zenciroglu A, Aydin M, Okumus N, Dursun A, Dilli D. Exchange transfusion for neonatal hyperbilirubinemia: an 8-year single center experience at a tertiary neonatal intensive care unit in Turkey. J Matern Fetal Neonatal Med 2015; 28 (13) 1537-1541
• 26 Du LZ. Subspecialty Group of Neonatology, Society of Pediatrics, Chinese Medical Association, Chinese Multicenter Study Coordination Group for Neonatal Bilirubin Encephalopathy. [Clinical characteristics of bilirubin encephalopathy in Chinese newborn infants-a national multicenter survey]. Zhonghua Er Ke Za Zhi 2012; 50 (05) 331-335
• 27 Ibekwe RC, Ibekwe MU, Muoneke VU. Outcome of exchange blood transfusions done for neonatal jaundice in abakaliki, South eastern Nigeria. J Clin Neonatol 2012; 1 (01) 34-37
• 28 Donneborg ML, Hansen BM, Vandborg PK, Rodrigo-Domingo M, Ebbesen F. Extreme neonatal hyperbilirubinemia and kernicterus spectrum disorder in Denmark during the years 2000-2015. J Perinatol 2020; 40 (02) 194-202
• 29 Duan L, Gan S, Hu H. A single-center experience on exchange transfusion therapy in 123 full-term cases of severe neonatal hyperbilirubinemia in Wuhan. J Matern Fetal Neonatal Med 2021; 34 (03) 466-472
• 30 Patra K, Storfer-Isser A, Siner B, Moore J, Hack M. Adverse events associated with neonatal exchange transfusion in the 1990s. J Pediatr 2004; 144 (05) 626-631
• 31 Romagnoli C, Zecca E, Papacci P, Vento G, Girlando P, Latella C. Which phototherapy system is most effective in lowering serum bilirubin in very preterm infants?. Fetal Diagn Ther 2006; 21 (02) 204-209
• 32 Viktorinova A. Iron-mediated oxidative cell death is a potential contributor to neuronal dysfunction induced by neonatal hemolytic hyperbilirubinemia. Arch Biochem Biophys 2018; 654: 185-193
• 33 Wu Y, Song J, Wang Y, Wang X, Culmsee C, Zhu C. The potential role of ferroptosis in neonatal brain injury. Front Neurosci 2019; 13: 115
• 34 Riordan SM, Shapiro SM. Review of bilirubin neurotoxicity I: molecular biology and neuropathology of disease. Pediatr Res 2020; 87 (02) 327-331
• 35 Iskander I, Gamaleldin R, El Houchi S. et al. Serum bilirubin and bilirubin/albumin ratio as predictors of bilirubin encephalopathy. Pediatrics 2014; 134 (05) e1330-e1339
• 36 Tsao PC, Yeh HL, Shiau YS. et al. Long-term neurodevelopmental outcomes of significant neonatal jaundice in Taiwan from 2000-2003: a nationwide, population-based cohort study. Sci Rep 2020; 10 (01) 11374
• 37 You J, Shamsi BH, Hao MC, Cao CH, Yang WY. A study on the neurodevelopment outcomes of late preterm infants. BMC Neurol 2019; 19 (01) 108
• 38 Geng J, Wang L, Zhang L. et al. Blood-brain barrier disruption induced cognitive impairment is associated with increase of inflammatory cytokine. Front Aging Neurosci 2018; 10: 129
• 39 Isa HM, Mohamed MS, Mohamed AM, Abdulla A, Abdulla F. Neonatal indirect hyperbilirubinemia and glucose-6-phosphate dehydrogenase deficiency. Korean J Pediatr 2017; 60 (04) 106-111
• 40 Liu Z, Yu C, Li Q. et al. Chinese newborn screening for the incidence of G6PD deficiency and variant of G6PD gene from 2013 to 2017. Hum Mutat 2020; 41 (01) 212-221
• 41 Alkén J, Håkansson S, Ekéus C, Gustafson P, Norman M. Rates of extreme neonatal hyperbilirubinemia and kernicterus in children and adherence to national guidelines for screening, diagnosis, and treatment in Sweden. JAMA Netw Open 2019; 2 (03) e190858
• 42 Wang J, Yin J, Xue M, Lyu J, Wan Y. Roles of UGT1A1 Gly71Arg and TATA promoter polymorphisms in neonatal hyperbilirubinemia: A meta-analysis. Gene 2020; 736: 144409